Horizon Therapeutics plc Announces First Subject Dosed in Phase I Trial Evaluating HZN-457 for the Treatment of Gout

Horizon Therapeutics plc announced the first subject has been dosed in a Phase I randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH.